Stephen J. Haggarty, PhD, serves as a faculty member in the Department of Neurology at Harvard Medical School and the Center for Genomic Medicine at Massachusetts General Hospital, where he is the director of the Chemical Neurobiology Laboratory, co-director of the Precision Therapeutics Unit, as well as the scientific director of neurobiology for the Center for the Neuroscience of Psychedelics in the Department of Psychiatry.

Sung Hee Choe is the managing director on the FasterCures team at the Milken Institute. She oversees the programmatic portfolio and is responsible for day-to-day operations.

Li Gan, PhD, is the director of the Helen and Robert Appel Alzheimer’s Disease Research Institute at Weill Cornell Medicine and the Burton P. and Judith B. Resnick Distinguished Professor in Neurodegenerative Diseases.

Diane Re is an assistant professor of environmental health sciences at the Columbia University School of Public Health. Re’s research team focuses on unraveling the environmental triggers and gene-environment interactions that lead to adult-onset neurodegenerative diseases, such as ALS and Parkinson’s disease.

Ayodola Anise is the senior director of operations for MI Health, supporting FasterCures, Public Health, Future of Aging, and Feeding Change. She brings over two decades of experience in advising on and implementing strategy, leading operations, developing staff, and collaborating for organizational effectiveness, efficiency, and equity.

Shane Liddelow is an assistant professor in the Department of Neuroscience and Physiology at the NYU Grossman School of Medicine. Liddelow’s basic research focuses on the role of non-neuronal cells in neuroinflammation that leads to neurodegeneration in diseases such as Alzheimer’s disease and ALS.

Clotilde Lagier-Tourenne is an associate professor of neurology at the Massachusetts General Institute for Neurodegeneration. Lagier-Tourenne’s lab focuses on basic science and uses a combination of genomic approaches across multiple model systems (animal models, neurons from patients, and post-mortem tissue) to identify mechanisms underlying ALS and frontotemporal dementia.

Steve Finkbeiner is director of the Center for Systems and Therapeutics and the Taube/Koret Center for Neurodegenerative Disease Research at Gladstone Institutes. Finkbeiner’s research is broadly focused across many neurodegenerative and psychiatric diseases.

Lucie Bruijn serves as the therapeutic area biomarker lead for amyotrophic lateral sclerosis (ALS) at Novartis UK.

Athena Rae Roesler is a director on the Public Health team at Milken Institute Health, where she leads a portfolio of work focused on prevention and chronic disease.